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Abstract
Background: Formation of site specific genomic double strand breaks (DSBs), induced by the expression of a pair of 
engineered zinc-finger nucleases (ZFNs), dramatically increases the rates of homologous recombination (HR) between 
a specific genomic target and a donor plasmid. However, for the safe use of ZFN induced HR in practical applications, 
possible adverse effects of the technology such as cytotoxicity and genotoxicity need to be well understood. In this 
work, off-target activity of a pair of ZFNs has been examined by measuring the ratio between HR and illegitimate 
genomic integration in cells that are growing exponentially, and in cells that have been arrested in the G2/M phase.
Results: A reporter cell line that contained consensus ZFN binding sites in an enhanced green fluorescent protein (EGFP) 
reporter gene was used to measure ratios between HR and non-homologous integration of a plasmid template. Both 
in human cells (HEK 293) containing the consensus ZFN binding sites and in cells lacking the ZFN binding sites, a 3.5 
fold increase in the level of illegitimate integration was observed upon ZFN expression. Since the reporter gene 
containing the consensus ZFN target sites was found to be intact in cells where illegitimate integration had occurred, 
increased rates of illegitimate integration most likely resulted from the formation of off-target genomic DSBs. 
Additionally, in a fraction of the ZFN treated cells the co-occurrence of both specific HR and illegitimate integration was 
observed. As a mean to minimize unspecific effects, cell cycle manipulation of the target cells by induction of a 
transient G2/M cell cycle arrest was shown to stimulate the activity of HR while having little effect on the levels of 
illegitimate integration, thus resulting in a nearly eight fold increase in the ratio between the two processes.
Conclusions: The demonstration that ZFN expression, in addition to stimulating specific gene targeting by HR, leads to 
increased rates of illegitimate integration emphasizes the importance of careful characterization of ZFN treated cells. In 
order to reduce off-target events, reversible cell cycle arrest of the target cells in the G2/M phase is an efficient way for 
increasing the ratio between specific HR and illegitimate integration.
Background
Currently, gene targeting by homologous recombination
(HR) is the standard method utilized for precise genome
modification of mammalian cells. In this strategy the cel-
lular DNA repair pathway, HR, mediates exchange of
sequences between a given donor DNA sequence and a
homologous genomic target sequence [1]. Although con-
ventional gene targeting is very successful in some appli-
cations like in the creation of transgenic mice, the
generally low frequencies of specific targeting events
makes the use of the technique limited to situations
where powerful selection and screening schemes can be
applied [2,3]. Technologies for obtaining high frequencies
of targeted sequence alteration in living cells have far
reaching implications for the construction of transgenic
cell lines and animals, both for the study of gene function
and for establishment of disease models. Furthermore,
direct modification of a target gene at its genomic loci at
high frequencies offers an appealing strategy for gene
therapy.
With the aim of developing methods for more efficient
and specific gene targeting, various alternative strategies
have been exploited including the use of modified donor
DNA, recombinant enzymes and modified viral vectors
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[4-6]. Nevertheless, the most successful approach by far is
based upon stimulating HR in the targeted cells through
formation of site specific DNA double-strand breaks
(DSBs). It has long been known that the formation of
DSBs in a target gene increases the rates of HR by up to
three orders of magnitude [7]. Lately, a strategy based on
the capacity of zinc-finger nucleases (ZFNs) to introduce
site specific DSBs has successfully been employed to sub-
stantially increase gene targeting rates [8-11]. ZFNs are
engineered proteins composed of modular zinc-finger
DNA binding domains coupled to the catalytic domain
from the FokI restriction endonuclease that will induce
site specific DSBs [12]. Each zinc-finger domain can spe-
cifically interact with three base pairs (bp) in the target
DNA and due to the requirement of the FokI catalytic
domain for dimerization, the composed recognition site
for a pair of three-finger ZFNs will be 18 bp (Fig. 1A)
[11,13]. Thus, by modifying the zinc-finger DNA binding
domains, it is possible to generate ZFNs that can induce
formation of specific DSBs in a broad range of DNA
sequences. Targeted genome modification by ZFNs has
successfully been achieved in cells form several species
including  Caenorhabditis elegans [14], Drosophila [15],
zebra fish [16,17], plants [18,19], rats [20] and humans
(including embryonic and induced pluripotent stem cells)
[8,21,22].
For practical applications of ZFN induced HR it is
essential that all possible adverse effects that ZFNs and
donor plasmids might have on the target genome are well
characterized. Formation of off-target genomic DSBs
could cause unwanted effects on the targeted genome
including, in the worst case, transformation due to
genetic rearrangements [23-25]. In this work the relation
between HR and non-homologous integration after ZFN
treatment was investigated in a model system based on a
mutated  enhanced green fluorescent protein (mEGFP)
gene in human embryonic kidney 293 cells. The donor
plasmid, given as a template for HR repair of the DSB
formed, also included an expression cassette for the puro-
mycin resistance (PuroR) gene. Accordingly, by quantify-
ing the number of puromycin resistant colonies formed
with and without expression of the ZFNs, the level of ille-
gitimate integration could be measured and used as an
indication of the specificity of the ZFNs. In 293-Flp-
mEGFP cells that contained the canonical ZFN binding
sites and in wild type (wt) 293 cells devoid of the ZFN
binding sites, the levels of illegitimate integration were
increased 3.5 fold upon ZFN exposure. Analysis of the
integrity of the mEGFP gene in puromycin resistant colo-
nies showed that the PuroR expression cassette had not
integrated at the position where the ZFNs were intended
to create a DSB. Interestingly, co-occurrence of both spe-
cific HR and illegitimate integration could be observed in
a fraction of ZFN treated cells. Importantly, transient cell
cycle arrest in the G2/M phase during ZFNs exposure did
not only boost rates of HR, but also increased the ratio of
specific HR versus illegitimate integration by nearly eight
fold.
Figure 1 Schematic representation of the model system. (A) Features of the mEGFP coding sequence (green) with binding sites for ZFN-Left (L) 
and ZFN-Right (R) indicated (dark and light blue, respectively). The positions of the mutations rendering the mEGFP gene non-functional are shown 
in red. The ZFN-L and ZFN-R bound to their target sequences are indicated, each with their zinc-finger domains (3 × red circles) and the FokI nuclease 
domain (orange circle). The two 9 bp long recognition sites for ZFN-L (GGG GTA CGC) and ZFN-R (GAA GCA GCA) are separated by a 6 bp spacer region 
required for optimal positioning of the two FokI nuclease domains. Given that the FokI nuclease domain must dimerize in order for a DNA DSB to be 
formed, the total recognition sequence required for DSB formation is 18 bp, excluding the 6 bp spacer region. The 293-Flp-mEGFP cell line contained 
a single copy chromosomally integrated mEGFP gene. (B) Arrangement of the mEGFP gene and surrounding genetic elements in the 293-Flp-mEGFP 
cell line including the human Elongation Factor 1a promoter (EF1a, black), the mEGFP gene (green) with the point mutations (red) and the poly-ade-
nylation signal (pA, red). The pDonor construct, provided as a substrate for HR, is shown as a circle with the regions homologous to the 293-Flp-mEGFP 
genomic sequence as indicated (ΔEGFP and pA, 1384 bp in total). The expression cassette for the PuroR gene is outlined in orange. Position and direc-
tion of the PCR primers used (P1, P2, P3, P-wt, Pu-1 and Pu-2) are indicated. With this model system, HR between the genomic mEGFP gene in the 293-
Flp-mEGFP cells and the ΔEGFP gene in the pDonor construct could be measured by quantification of green fluorescent cells, while the rate of illegit-
imate integration could be quantified by appearance of puromycin resistant clones.
mEGFP:
FokI
3  x  zinc-fingers
ZFN-L ZFN-R
Zinc-finger  nuclease
9  bp 9  bp 6  bp
Total  recognition  site 
for  ZFN-L  and  -R
A
P-wt
Pu-1 Pu-2
293-Flp-mEGFP  genome:
pDonor:
DEGFP pA
PuroR
1384  bp
EF1a mEGFP pA
B
P1 P3 P2Olsen et al. BMC Molecular Biology 2010, 11:35
http://www.biomedcentral.com/1471-2199/11/35
Page 3 of 11
Results
Stimulation of targeted gene correction by concurrent 
expression of ZFN-Left and ZFN-Right
T o study the use of ZFNs in gene targeting, human 293
cells containing a single copy of a chromosomally inte-
grated mEGFP gene were created and named 293-Flp-
mEGFP. The mEGFP gene in the 293-Flp-mEGFP cell line
does not encode for a functional EGFP protein due to the
introduction of a premature stop codon together with a
two bp deletion in the EGFP coding sequence (CDS) (Fig.
1A). The two ZFNs used in this study, ZFN-Left (L) and
ZFN-Right (R) have been constructed by assembly of sin-
gle zinc-finger modules as previously described [8]. The
expressed ZFN proteins each consisted of a three-finger
zinc finger DNA binding domain coupled to the non-spe-
cific catalytic domain from the FokI nuclease (Fig. 1A).
Binding of the two ZFNs to their target sequences in the
mEGFP gene would lead to the formation of a genomic
DSB, a type of DNA damage that is known to stimulate
HR when a homologous donor sequence is available as
template for repair. The donor plasmid (pDonor) used
contained a truncated wt EGFP gene (ΔEGFP) lacking the
first seven bases of the EGFP CDS (Fig. 1B). In addition
the pDonor construct incorporated an expression cas-
sette for the PuroR gene that upon stable genomic inte-
gration would make the target cells resistant to selection
with puromycin (Fig. 1B).
In non-transfected and in 293-Flp-mEGFP cells trans-
fected with the ZFNs alone, no green cells could be
detected (detection limit ~1 in 100 000) (Fig. 2). These
results demonstrated that our cellular system was with-
out leakage and with no spontaneous background fluo-
rescence. When 293-Flp-mEGFP cells were transfected
with the pDonor alone or with pDonor together with
either ZFN-L or ZFN-R individually, 0.02% green cells
were observed (Fig. 2). Given that control transfection of
wt 293 cells with pDonor alone also produced 0.01%
green cells (not shown) this level of fluorescent cells rep-
resented the background fluorescence produced from the
pDonor construct. However, when both ZFNs were
transfected together with the pDonor, the number of
green cells increased by 9 fold (to 0.17%) compared to
what was obtained with pDonor alone (Fig. 2). These
results verified the previously reported stimulation of HR
by ZFNs and also confirmed the dependence of binding
of both ZFN-L and ZFN-R to their respective target sites
in order to produce a specific DSB in the target mEGFP
gene [9-11]. Although other authors have reported higher
rates of ZFN mediated stimulation of targeted gene cor-
rection [8,26], our results confirmed the stimulation of
HR by ZFNs and established the applicability of our
model system to investigate ZFN mediated gene correc-
tion.
Effects of ZFNs on illegitimate integration
With the aim of characterizing the specificity of the
ZFNs, the levels of illegitimate integration of the pDonor
was measured by quantifying the number of cells that
acquired puromycin resistance after transfection of the
pDonor along with the ZFNs. The rationale for this is that
genomic DSBs tend to capture foreign DNA [27-29] and
consequently, if the expression of ZFNs would induce the
formation of off-target DSBs, increased levels of illegiti-
mate integration of the pDonor would be expected. To
verify that off-target genomic DSBs would lead to
increased numbers of puromycin resistant colonies in our
system, 293-Flp-mEGFP cells were transfected with pDo-
nor and treated with etoposide, a topoisomerase II inhib-
itor known to induce the formation of DSBs [30]. As seen
in Fig. 3A, etoposide treatment of 293-Flp-mEGFP cells
transfected with pDonor resulted in a 4.6 fold increase in
the number of puromycin resistant colonies. This verified
that formation of genomic DSBs led to increased rates of
illegitimate integration. Next, a potential general cytotox-
icity of the ZFN-L and ZFN-R was quantified by measur-
ing the plating efficiency (PE). Transfection of 293-Flp-
mEGFP cells with ZFNs did not have a significant effect
(P < 0.05) on the PE (not shown). Nevertheless, all further
measurements of illegitimate recombination were nor-
malized towards the PE obtained following the respective
treatments.
Quantification of the number of puromycin resistant
colonies formed after transfection of 293-Flp-mEGFP
cells with various combinations of pDonor, ZFN-L and
ZFN-R are shown in Fig. 3B. Transfection of pDonor
Figure 2 Stimulation of targeted gene correction by ZFNs. 293-
Flp-mEGFP cells with a single genomic copy of the mEGFP target (black 
line) were transfected with the pDonor (green line) and ZFN constructs 
(four red circles) as indicated below the bars. Gene correction as a re-
sult of HR between the genomic mEGFP target and the ΔEGFP in the 
pDonor was measured 72 hours after transfection by flow cytometric 
quantification of green cells. For each flow cytometric analysis at least 
100 000 cells were measured. Each bar represents mean ± SD from 
three parallels.
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alone produced a rate of 28 × 10-5 puromycin resistant
colonies (per treated cell). When either ZFN-L or ZFN-R
was individually transfected with the pDonor, an increase
in the frequencies of puromycin resistant colonies to 55 ×
10-5 was observed. Compared to the level of illegitimate
integration obtained with the pDonor alone this increase
was not statistically significant (P = 0.084). However,
when 293-Flp-mEGFP cells were transfected with both
ZFN-L and ZFN-R simultaneously together with pDonor,
a significant increase (up to 99 × 10-5) of puromycin resis-
tant colonies could be observed (P = 0.020). As a further
control of the specificity of the ZFNs, their influence on
illegitimate integration was also quantified in wt 293 cells
that did not contain the mEGFP target gene incorporat-
ing the canonical ZFN binding sites. When wt 293 cells
were transfected with either ZFN-L or ZFN-R individu-
ally along with the pDonor construct, no increase in ille-
gitimate integration could be observed (Fig. 3C).
Figure 3 Analysis of illegitimate genomic integration of the donor plasmid in ZFN treated cells. (A) Effect of etoposide treatment on the levels 
of illegitimate integration of the PuroR expression cassette from the pDonor in the genome of 293-Flp-mEGFP cells. After transfection with pDonor, 
cells were either left untreated or treated with etoposide before selection with puromycin in order to quantify the levels of illegitimate integration. As 
a control for the selection conditions, non-transfected cells were also included. Each bar represents the mean rate of puromycin resistant (R) cells ± 
SD from three parallels. (B) Quantification of illegitimate integration in 293-Flp-mEGFP cells after transfection with pDonor along with pZFN-L and 
pZFN-R. Controls included non-transfected cells and cells transfected with pZFNs or pDonor individually as indicated below the bars. The rates of il-
legitimate integration were normalized according to variations in PE. Statistical P values (paired t-test) comparing the means of the indicated bars are 
shown and an asterisk marks significant difference (P < 0.05). (C) Analysis of illegitimate genomic integration of the pDonor in wt 293 cells that did not 
enclose the mEGFP target sequence in their genome. Cells were transfected with pDonor, pZFN-L and pZFN-R as indicated below the bars and ana-
lyzed as in B. (D) Analysis of illegitimate genomic integration of the pDonor in wt 293 cells after transfection with an I-SceI endonuclease expression 
construct (pI-SceI). Cells were transfected with pDonor together with 100 ng of pI-SceI. The frequency of illegitimate integration was quantified as in B.
-5
eR
Rat
 
of 
puromycin 
 
cells 
(x10
)
0.0
5.0
20.0
25.0
30.0
35.0
15.0
10.0
40.0
45.0
non 
transfected
pDonor pDonor
+
etoposide
AB
-5
eR
Rat
 
of 
puromycin 
 
cells 
(x10
)
0.0
20.0
40.0
60.0
80.0
100.0
120.0
P=0.084
mEGFP:
P=0.020*
293-Flp-mEGFP:
C
-5
Ra
e 
of 
pur
cin 
R 
el
s(
1
to
m
y
c
l
 
x0
)
P=0.017  *
pZFN-L:
pZFN-R:
pDonor:
+
+
+
+ +
+
++ + +
0.0
5.0
10.0
15.0
20.0
25.0
293  wt:
D
-5
Ra
e 
of 
pur
ycin 
R 
el
s 
(x10
to
m
c
l
)
++
++
293  wt:
0.0
5.0
10.0
15.0
20.0
25.0
pI-SceI:
pDonor:
P=0.008  *
293-Flp-mEGFP:Olsen et al. BMC Molecular Biology 2010, 11:35
http://www.biomedcentral.com/1471-2199/11/35
Page 5 of 11
However, in agreement with the results form the 293-Flp-
mEGFP cell line, when both ZFN-L and ZFN-R were
transfected together with the pDonor plasmid, a 3.6 fold
increase in the number of puromycin resistant colonies
was observed.
We next wanted to compare the observed ZFNs medi-
ated increase of illegitimate integration with the effect of
the I-SceI endonuclease. The yeast I-SceI endonuclease
has an 18 bp recognition sequence that is rarely found in
mammalian genomes and the endonuclease displays high
specificity [7,31,32]. When the I-SceI expression con-
struct were introduced into wt 293 cells together with the
pDonor plasmid, a 1.8 fold increase in the frequency of
illegitimate integration of the donor could be observed
(Fig. 3D). As the protein expression levels of the ZFNs
and I-SceI were not measured and as the cleavage kinetics
of the ZFNs and the I-SceI might differ, the levels of ille-
gitimate integration mediated by the ZFNs and I-SceI can
not be compared directly. However, given that I-SceI is
known to be very specific [7,31,32], the observed increase
of illegitimate integration both by SceI (1.8 fold) and
ZFNs (3.6 fold) when similar amounts of the expression
constructs were used (100 ng pI-SceI versus 50 ng of each
the two ZFNs) indicated that the specificity of the ZFNs
and SceI are within a comparable range.
Thus, by measuring the levels of genomic integration of
the donor plasmid it was established that expression of
the here tested ZFNs produced a 3.5-3.6 fold increase of
the levels of illegitimate integration. The relative increase
of ZFN mediated illegitimate integration was found to be
independent of the presence of canonical ZFNs binding
sites in the genome of the targeted cells.
Analysis of the genomic integration sites of the PuroR 
cassette in 293-Flp-mEGFP cells
To investigate whether the observed increase rates of ille-
gitimate integration after ZFN exposure was due to an
integration of the PuroR  cassette into the genomic
mEGFP gene, PCR analysis of the genomic DNA from 25
puromycin resistant colonies was performed. In two sep-
arate PCR analyses using the same forward primer (P1 in
Fig. 1B), specific to the first bases in the genomic mEGFP
gene, and primers specific for the PuroR gene either in
forward or reverse orientation (Pu-1 or Pu-2 in Fig. 1B),
no amplification products were obtained (Fig. 4A). In a
positive control PCR using a plasmid template, the func-
tionality of the primers and PCR conditions used were
verified (Fig. 4A ctr). Accordingly, the failure to produce
an amplification product from the genomic DNA was
most likely due to the absence of the PuroR sequence in
the mEGFP gene. To further test whether the genomic
mEGFP in the puromycin resistant colonies was intact,
PCR analysis of the puromycin resistant colonies with
primers flanking the mEGFP gene (P2 and P3 in Fig 1B)
was carried out. PCR analysis of the puromycin resistant
colonies with primers P2 and P3 produced an amplifica-
tion product of approximately 600 bp corresponding to
the expected size of an uninterrupted mEGFP gene (610
bp) in all the 25 colonies (not shown). Taken together
these results established that the increased rates of illegit-
imate integration following ZFN expression was not due
to genomic integration of the PuroR  cassette in the
genomic mEGFP site where the ZFNs were designed to
form a DSB. Given that that the average occurrence of the
canonical 18 bp ZFN recognition sequence statistically is
only one in the mammalian genome, the observed
increased rates of illegitimate integration following ZFN
Figure 4 Analysis of the PuroR genomic integration site in 293-
Flp-mEGFP cells. (A) The integrity of the mEGFP gene in non-green 
puromycin resistant colonies of 293-Flp-mEGFP cells was analyzed af-
ter transfection with pDonor together with the ZFNs. Genomic DNA 
isolated from 25 individual colonies was subjected to PCR using primer 
pairs as indicated above the panels. The genomic mEGFP specific prim-
er (P1) was used together with the puromycin specific primers in op-
posite orientations (Pu-1 and Pu-2). Control PCR's (rightmost gel, ctr) 
using pEGFP-BABE-puro as template was performed with the primer 
pairs: P-amp + Pu-1 (lane 1), P1 + Pu-1 (lane 2), P1 + Pu-1 without tem-
plate (lane 3) and PCR amplification produced the anticipated amplifi-
cation products (2364 bp, 1429 bp and no product) verifying that 
primers worked under the given conditions. (B) PCR analysis of ge-
nomic DNA from 26 individual colonies displaying both green fluores-
cence (HR) and puromycin resistance (illegitimate recombination) 
after transfection with the pDonor and ZFNs. The genomic mEGFP spe-
cific primer (P1) was used together with the puromycin specific prim-
ers (Pu-1 and Pu-2) to investigate if the ΔEGFP and PuroR cassette had 
integrated in the genome of the 293-Flp-mEGFP cells as a single frag-
ment or not. M represents the size marker and sizes of relevant bands 
are specified. Position of the PCR reactions from the individual colonies 
is indicated below the lanes.
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expression was most likely due to formation off-target
genomic DSBs by the ZFNs.
Simultaneous occurrence of specific gene correction and 
illegitimate integration
Generally, the repair of genomic DSBs is carried out by
either the HR or the non-homologous end joining (NHEJ)
repair pathway [33]. However, the two pathways are not
mutually exclusive, and crosstalk as well as co-operation
between the two pathways has been demonstrated [34-
36]. To determine whether both HR and illegitimate inte-
gration had occurred in individual cells transfected with
ZFNs, an assay enabling the detection of both events in
the same cells was established. After transfection of 293-
Flp-mEGFP cells with the pair of ZFNs along with pDo-
nor, green cells resulting from specific HR were isolated
by fluorescent activated cell sorting (FACS). Subse-
quently, the green cells (where HR had occurred) and
non-green cells (where HR had not occurred) were put
under puromycin selection for quantification of the level
of illegitimate genomic integration of the pDonor. When
the frequency of illegitimate integration in the two popu-
lations was compared, similar levels of illegitimate inte-
gration were observed in both the green and the non-
green populations of cells (not shown).
In the green fluorescent 293-Flp-mEGFP cells that also
exhibited puromycin resistance, both the ΔEGFP and the
PuroR  regions from the pDonor construct must have
been stably integrated into the genome of the target cells.
Theoretically, the ΔEGFP and PuroR segments from the
pDonor could either have been integrated jointly as a sin-
gle fragment or they could have been integrated as multi-
ple fragments. Given that the analyzed cells displayed
green fluorescence due to HR between the genomic
mEGFP gene and the ΔEGFP region in the pDonor, inte-
gration of the ΔEGFP and PuroR regions as a single frag-
ment would require that the PuroR  region to be
positioned downstream (3') of the mEGFP gene (Fig. 1B).
To study how the pDonor had integrated, PCR analysis of
the mEGFP and 3' downstream regions was performed.
When primer P1 (Fig. 1B), specific for the initial
sequences of the genomic mEGFP  target was used
together with primers specific for the PuroR cassette in
the donor (Pu-1 and Pu-2, Fig. 1B), PCR amplification
products were obtained from 2 of the 26 clones analyzed
(lane 7 and 18 in Fig. 4B). The size of the 2 amplification
products were around 4500 bp which corresponds to the
expected size (4389 bp) if the ΔEGFP and PuroR regions
from the pDonor was integrated as a single fragment. The
lack of PCR products in 24 of the analyzed clones indi-
cated that the PuroR cassette has not integrated immedi-
ately downstream of the genomic mEGFP  gene. As a
control of the quality of the genomic DNA and as a con-
firmation of the FACS sorting, PCR analysis using primer
P1 together with an allele specific primer (P-wt, Fig. 1B)
only hybridizing to the wt EGFP  was performed. An
amplification product with the expected size (260 bp) was
obtained in 24 of the 26 colonies analyzed (not shown).
Taken together, the analysis of the quality of the HR
reaction established that in the majority (92%) of the
clones that had undergone concurrent HR and illegiti-
mate recombination, the ΔEGFP region and the PuroR
region from the pDonor construct had been incorporated
in the genome via multiple integration events. Only in 8%
of the clones the ΔEGFP  and  PuroR regions had inte-
grated as a single fragment "in frame" with the genomic
mEGFP. Our observed genomic incorporation of both
homologous and non-homologous sequences at a DSB in
8% of the clones is in accordance with Richardson et al.
who demonstrated that a DSB repair event could be initi-
ated by homologous invasion at one side and completed
by NHEJ at the other end [36].
Effects of transient G2/M cell cycle arrest on gene 
correction and illegitimate integration
Cell cycle status is an important factor in the decision
w h e t h e r  a  g e n o m i c  D S B  i s  r e p a i r e d  b y  H R  o r  N H E J .
W hile  NHEJ  is  a cti ve  t hr ou gho ut  t he  c e ll  cyc le ,  HR  is
mainly active in the late S and G2/M phases [37]. To
examine the influence of cell cycle phase on the levels of
both HR and illegitimate integration, 293-Flp-mEGFP
cells were arrested in the G2/M cell cycle phase by the
microtubule-depolymerizing drug nocodazole, that
reversibly arrests cells in the G2/M phase [38]. As seen in
Fig. 5A, incubation of cells with nocodazole for 24 hours
resulted in a clear accumulation of cells in the G2/M cell
cycle phase (middle panel). After removal and further
incubation for 48 hours without nocodazole, cells reen-
tered normal proliferation (right panel) and displayed a
cell cycle profile equivalent to untreated cells (left panel).
When the percentage of ZFN induced green cells was
compared between exponentially growing and in G2/M
arrested 293-Flp-mEGFP cells, a 5.8 fold increase of HR
was observed in the G2/M arrested cell (from 0.12% to
0.70%) (Fig. 5B). The observed differences in HR was not
due to differences in the transfection efficiencies as trans-
fection with a wt EGFP expression plasmid (pEGFP-c1)
displayed similar frequencies both in untreated and
nocodazole treated cells (not shown). Increased rates of
HR following nocodazole induced G2/M cell cycle arrest
are in agreement with Urnov et al. who observed
increased levels (4.8 fold) of ZFN mediated HR in cells
reversely arrested in the G2/M phase using vinblastine
[8].
When the rate of illegitimate integration was compared
between exponentially growing and G2/M arrested cells,
only minor variations was observed (Fig. 5C). Conse-
quently, when the ratio of HR versus illegitimate integra-Olsen et al. BMC Molecular Biology 2010, 11:35
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tion was calculated, transfection of cells with pDonor and
both ZFNs produced a nearly eight fold increased ratio in
favor of HR in cells that had been arrested in the G2/M
phase (Fig. 5D). Thus, reversible arrest of the target cells
in the G2/M cell cycle phase can be an efficient way to
increase the ratio between HR and illegitimate integra-
tion.
Discussion
S t i m u l a t i o n  o f  t a r g e t e d  g e n o m e  m o d i f i c a t i o n  b y  ZF N s
has proven to be very successful [39]. Nevertheless, geno-
toxicity of ZFNs is still an important issue. Several
reports have demonstrated substantial toxicity upon
expression of ZFNs [10,26,40-45] while other publica-
tions claim relative minor levels of ZFN toxicity [8,15,46].
It is known that the formation of genomic DSBs induce
cell cycle arrest and cell death [33], and a correlation
between ZFN specificity and genotoxicity has been dem-
onstrated [15,41]. In addition it has been shown that the
presence of a genomic DSB triggers a multitude of DNA
damage response signaling pathways and changes the
activity of numerous central cellular proteins [47,48].
ZFN design, assembly and target sequences are impor-
tant variables determining the specificity and potential
genotoxic side effects of ZFNs [49-51]. Thus, two zinc-
finger modules produce ZFNs with greater specificity
compared to ZFNs assembled from single zinc-finger
modules [52]. Publications using ZFNs assembled from
two zinc-finger modules generally report low levels of
cytotoxicity [8,18,22,46]. Also, generation of ZFNs by
Figure 5 Effects of G2/M arrest of the target cells on gene correction and illegitimate integration. (A) Cell cycle profiles of exponentially grow-
ing, nocodazole arrested, and nocodazole arrested and subsequently released 293-Flp-mEGFP cells (left, middle and right panels, respectively). Histo-
grams displaying the distribution of the DNA content of treated cells as measured by propidium iodide (PI) staining are shown. (B) Quantification of 
gene correction in exponentially growing (black bars) and G2/M arrested (gray bars) 293-Flp-mEGFP cells after transfection with pDonor, pZFN-L and 
pZFN-R as indicated. The amount of green cells was measured 72 hours after transfection by flow cytometry as in Fig. 2. (C) Quantification of illegiti-
mate integration in exponentially growing (black bars) and G2/M arrested cells (grey bars). Cells were treated as in B and the level of illegitimate inte-
gration was quantified by measuring the number of puromycin resistant colonies formed as in Fig. 3B. The results presented are normalized for 
different PE in the untreated and G2/M arrested cells. (D) Presentation of the ratio between HR and illegitimate integration in exponentially growing 
(black bars) and G2/M arrested cells (grey bars). The ratio was calculated from the results in B and C.
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modular assembly of single-finger modules as provided
by the Oligomerized Pool Engineering (OPEN) platform
has generated efficient ZFNs with low levels of toxicity
[19,53-56]. To study the genotoxicity of ZFNs various
strategies have been employed. Quantification of cell sur-
vival [10,41,49] and apoptosis [26] offers a relatively
crude measurement of potential side effects mediated by
ZFNs, while quantification of genomic DSBs by detection
of proteins normally recruited in DSB repair foci (e.g. γ-
H2AX and p53 tumor suppressor binding protein 1)
offers a more precise information to the mechanism that
induce the toxicity [41,42,45,57]. We have previously
used cell cycle analysis, quantification of γ-H2AX and
direct detection of DSBs by a comet assay to assess ZFN
mediated toxicity [58]. In the present work, the specificity
of a pair of three-finger EGFP specific ZFNs has been
investigated by measuring their influence on the levels of
illegitimate integration of the given donor plasmid. We
have shown that upon expression of the ZFNs in human
293 cells, the levels of illegitimate integration of the
donor plasmid was increased by about 3.5 fold in cells
containing the canonical ZFN binding sites and in cells
devoid of the ZFN target sequences. In cells that con-
tained the canonical ZFN binding sites, genomic analysis
of the mEGFP target gene revealed that the donor DNA
had not integrated at the position where the ZFNs where
intended to form a DSB (Fig. 4A). Consequently, the
observed increase in illegitimate integration upon expres-
sion of the ZFNs was most likely due to formation of off-
target DSBs by the ZFNs. It has been beyond the scope of
this work to characterize the precise mechanism leading
to the formation of the off-target DSBs and therefore the
integration sites of the PuroR  cassette have not been
mapped. However, it has been shown that formation of
o f f -t a r g e t  DS B s  b y  ZF N s  c a n  t a k e  p l a c e  i f  ZF N s  f o r m
homodimers, or if a pair of ZFNs binds to sites that are
slightly different from the canonical 18 bp recognition
sequence [59]. Furthermore, it is possible that off-target
DSBs can form if only one ZFN binds to its 9 bp canonical
recognition site while the second ZFN remains in solu-
tion, as observed with the native FokI restriction enzyme
[60].
It is reaffirming for the technology, that we did not
observe measurable cytotoxic effects on cells that had
been transfected with the given ZFN constructs (no
changes in PE). In addition, the levels of illegitimate inte-
gration obtained with the ZFNs, although present, were
only moderately increased compared to the benchmark I-
SceI endonuclease. Interestingly, Moehle et al. have
recently shown that increasing doses of a pair of four-fin-
ger ZFNs did not lead to increased rates of illegitimate
integration [46].
The main impediment in gene targeting approaches is
the unfavorable ratio between high frequency of illegiti-
mate integration and low frequency of specific HR [3]. By
enabling the formation of genomic DSB in the target
gene, ZFNs allow to significantly stimulate the rates of
HR. However, as shown in this work, illegitimate integra-
tion still takes place and further means of increasing the
rates of HR relative to illegitimate integration would be
valuable. In the context of ZFN mediated gene correc-
tion, arresting cells in the G2/M phase has been shown to
stimulate the rates of HR [8]. On the other hand, the
influence of a G2/M arrest on the levels of ZFN mediated
illegitimate integration has not been investigated. Our
work showing that levels of illegitimate integration were
almost unaffected by a reversible G2/M arrest of the tar-
get cells (Fig. 5C) is in agreement with publications show-
ing that a G2/M cell cycle arrest did not influence on the
activity of the NHEJ pathway [61]. Thus, the demonstra-
tion that reversible G2/M cell cycle arrests leads to a
nearly eight fold increase in the ratio between specific HR
and illegitimate integration (Fig. 5D) present an effective
strategy to influence the activity of DNA repair pathways
in order to achieve high levels specific ZFN mediated
gene correction along with low levels of illegitimate inte-
gration.
By enabling the formation of site specific genomic DSBs
over a range of genomic targets, the development of
ZFNs has brought the field of targeted genome modifica-
tion a substantial step forward. Next generation ZFNs
with further improved properties [62] as exemplified by
c r e a t i o n  o f  Z F N s  a c t i v e  o n l y  a s  h e t e r o d i m e r s  [ 4 2 , 4 5 ] ,
along with generation of ZFNs with increased numbers of
zinc-finger DNA binding modules [42,46,63,64], corrobo-
rate that ZFNs have a realistic potential for evolving into
a valuable tool for functional genomics [20], biotechnol-
ogy [18] and human gene therapy [57].
Conclusions
The demonstration that ZFNs in addition to stimulate
specific gene targeting by HR also can produce increased
rates of illegitimate integration emphasizes the impor-
tance of cautious characterization of cells that have been
treated with ZFNs. Reversible cell cycle arrest of the ZFN
targeted cells in the G2/M phase is a simple and efficient
way of positively altering the ratio between specific HR
and illegitimate integration.
Methods
Plasmids
The ZFN target plasmid pcDNA4/TO/mutEGFP, and the
expression plasmids for ZFN-L and ZFN-R (driven by
CMV promoter) were generously provided by Samgamo
BioSciences, Inc. (Richmond, California) and have been
described elsewhere [8]. The mutEGFP  (mEGFP) gene
codes for a non-functional EGFP protein due to the pres-
ence of a premature stop codon (GAC to TAA) at posi-Olsen et al. BMC Molecular Biology 2010, 11:35
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tion 229-231 and a two bp deletion (AT to --) at position
235-236 in the EGFP CDS. The pFRT/mEGFP construct
used for making the 293-Flp-mEGFP cell line was made
by cloning the mutEGFP sequence into pEF5/FRT/V5-D-
TOPO (Invitrogen, Carlsbad, California). pFRT/EGFP
(expressing wt EGFP) was made by cloning the wt EGFP
CDS from pEGFP-c1 (Clontech Mountain View, CA) into
the same construct. The pDonor construct incorporated
a truncated EGFP  sequence (promoterless) lacking the
first seven bases (ΔEGFP) together with a PuroR expres-
sion cassette that had been cloned into pBluescript-SK
(Stratagene, Cedar Creek, Texas) (Fig. 1B). The pEGFP-
BABE-puro construct used in the control PCR in Fig. 4A
was made by cloning the EGFP CDS from pEGFP-c1 into
the pBABE-puro [65] construct. The expression plasmid
for the I-SceI nuclease (driven by CMV promoter) was
generously provided by Dr. Jasin [66]
Cell lines
The wild type human embryonic kidney cell line (HEK
293, CRL-1572), was purchased from ATCC (ATCC-
LGC, Boras, Sweden). The 293-Flp-mEGFP cell line, con-
taining a single copy genomic integration of the mutated
EGFP (mEGFP) gene, was generated by using Invitrogen's
Flp-In system according to their instructions. Briefly, the
stable 293-Flp-In cell line (Invitrogen, Carlsbad, Califor-
nia) that contains a single copy genomic integration of the
Flp recombination target (FRT) site was transfected with
the expression construct for the Flp recombinase
(pOG44) together with the plasmid containing the
mEGFP gene and a FRT site (pFRT/mEGFP). As a result
of Flp recombinase mediated recombination, the mEGFP
gene will be integrated in the genomic FRT site of the
293-Flp-In cells where its expression is driven by the
human Elongation Factor 1α (EF1α) promoter (Fig. 1B).
All cell lines were grown in DMEM containing 10% FBS
and 1% penicillin-streptomycin at 37°C in a humidified
atmosphere containing 5% CO2.
Analysis of ZFN mediated genomic gene correction and 
illegitimate integration in 293-Flp-mEGFP cells
Cells were transfected in 12 well plates with pDonor (0.5
μg), pZFN-L and pZFN-R (0.05 μg each) as indicated in
the figures. The total amount of DNA in each well was
adjusted to be 0.6 μg by addition of the pBlueskript vector
(Stratagene, Cedar Creek, Texas). Transfection was done
using Lipofectamine (LF) 2000 (Invitrogen) according to
the manufactures instructions (2.0 μl LF2000 pr. well,
kept on the cells overnight). Two days after transfection,
cells were plated out both in new 12 well plates for analy-
sis of HR and in 60 mm dishes (600 000 cells/dish) for
analysis of illegitimate integration. For analysis of HR, the
a m o u n t  o f  gr ee n  c e l ls  was  q ua n t i fi ed  ( t h r ee  da ys  a ft e r
transfection) on a Partec PAS flow cytometer (Partec
GmbH, Münster, Germany). Cell sorting was performed
with the FACSaria cell-sorting system (BD Biosciences,
Franklin Lakes, New Jersey). For analysis of illegitimate
integration of the pDonor plasmid, cells were grown in
the presence of 1.0 μg/ml puromycin (Sigma-Aldrich,
Inc., St. Louis, Missouri). Following 10 days of growth in
selective medium, puromycin resistant colonies were
visualized by methylene blue staining (0.2% in methanol,
5 min on the cells) and quantified using the GeneTools
image analysis software (Syngene, Cambridge, UK).
Etoposide treatment of cells
One day after transfection of 293-Flp-mEGFP cells with
pDonor, cells were incubated overnight with growth
medium containing 0.1 μM etoposide (Sigma-Aldrich).
Three days after transfection the cells were plated in 60
mm dishes for puromycin selection and for measurement
of the PE as described below. Etoposide treatment of the
cells did not influence the PE (not shown).
Quantification of cytotoxicity by measurement of plating 
efficiency (PE)
PE was determined by plating 20 cells/cm2 in complete
growth medium in 60 mm dishes. Following 14 days of
expansion, the number of colonies formed was counted
and the percentage of colony forming cells was calcu-
lated.
PCR analysis of genomic integration sites
Following transfection of 293-Flp-mEGFP cells with pDo-
nor together with ZFNs, analysis of the integrity of the
mEGFP gene in non-green puromycin resistant 293-Flp-
mEGFP cells was done by PCR analysis on their genomic
DNA (Fig. 4A). Three days after transfection, non-green
cells were isolated by FACS, replated and subjected to
puromycin selection as described. Genomic DNA from
the expanded colonies was isolated (Illustra blood
genomicPrep kit; GE Healthcare, Chalfont St. Giles, UK)
and used as template (0.5 μg) for PCR amplifications
using the primers as indicated. Analysis of the quality of
the HR reaction in cells displaying both green fluores-
cence and puromycin resistance (Fig. 4B) was performed
on genomic DNA from 293-Flp-mEGFP cells that had
been transfected with pDonor along with the ZFNs. The
sequences of the primers used were the following (5' to
3'): P1: ata tcg gtc gcc acc atg gtg a; P2: ccc atc ctg gtc gag
ctg ga; P3: cgc gct tct cgt tgg ggt ct; Pu-1: gcc cga cgc gcg
tga gga aga gtt ctt; Pu-2: cgc gca tgg ccg agt tga g; P-amp:
cca ctt ctg cgc tcg gcc ctt c; P-wt (gtc gtg ctg ctt cat gtg
gtc). PCR amplifications were performed using the Phu-
sion DNA high fidelity DNA polymerase (Finnzymes,
Espoo, Finland) using the following cycling parameters:
98°C for 2 min, 30 cycles of 98°C for 15 seconds (sec),
72°C for X min/sec and final elongation at 72°C for 7 min.Olsen et al. BMC Molecular Biology 2010, 11:35
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The elongation time (X) varied according to the primer
pairs used. For amplification using the P1 together with
Pu-1 or Pu-2 X was 4 min. For PCR with primer P2 and
P3, X was 30 sec and in the control PCR using P1 + Pu-1
and P-amp + Pu-2, X was 2 min.
Transient G2/M arrest and cell cycle analysis
293-Flp-mEGFP cells were arrested in the G2/M phase by
incubation with nocodazole (Sigma-Aldrich). Nocoda-
zole (0.1 μg/ml) was applied to the cells together with the
transfection mixture and was kept on the cells for 24
hours before the cells were allowed to re-enter cell
cycling. Cell cycle analysis was done on fixed cells (70%
EtOH) stained with propidium iodide (PI) (20 μg/ml PI,
200 μg/ml RNaseA, 0.1% Triton-X100). Cells were
replated for quantification of illegitimate integration and
PE two days after transfection as described. The PE for
exponentially growing cells was 33% while for G2/M
arrested cells the PE was 5%.
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